Kisqali is a prescription drug used with other medications to treat certain kinds of breast cancer. Kisqali can cause side effects that range from mild to serious, such as fatigue, hair loss, and ...
Novartis' CDK4/6 inhibitor Kisqali has claimed a broad FDA approval in early breast cancer that could give it an edge over class rival Verzenio from Eli Lilly. The US regulator has cleared Kisqali ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback